Determinants of survival in HER2+ metastatic esophagogastric cancer.
Steven B MaronWalid K ChatilaHenry S WalchJoanne F ChouNicholas CegliaRyan N PtashkinRichard Kinh Gian DoViktoriya ParoderNeeta Pandit-TaskarJason S LewisTiago Biachi de CastriaShalom SabwaFiona SocolowLara FederJasmine ThomasIsabell SchulzeKwanghee KimArijh ElzeinViktoria BojilovaMatthew ZatzmanUmeshkumar K BhanotRebecca J NagyJeeyun LeeMarc SimmonsMichal SegalGeoffrey Y KuDavid H IlsonMarinela CapanuJaclyn Frances HechtmanTaha MerghoubSohrab P ShahNikolaus SchultzDavid B SolitYelena Y JanjigianPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
These findings highlight the clinical relevance of identifying baseline intrapatient heterogeneity and serial ctDNA monitoring of HER2-positive EG cancer patients to identify early evidence of treatment resistance, which could guide proactive therapy escalation or de-escalation.